Wells Fargo & Company Ikena Oncology, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.27 - $2.0 $1,783 - $2,808	1,404 Added 14.82%	10,880 $15,000
Q4 2023 Feb 09, 2024	BUY	$1.33 - $4.4 $4,450 - $14,722	3,346 Added 54.58%	9,476 $18,000
Q3 2023 Nov 13, 2023	SELL	$4.09 - $6.43 $8,576 - $13,483	-2,097 Reduced 25.49%	6,130 $26,000
Q2 2023 Aug 15, 2023	BUY	$3.5 - $7.31 $27,839 - $58,143	7,954 Added 2913.55%	8,227 $53,000
Q1 2023 May 12, 2023	BUY	$2.62 - $4.97 $7 - $14	3 Added 1.11%	273 $0
Q4 2022 Feb 13, 2023	BUY	$2.0 - $3.7 $8 - $14	4 Added 1.5%	270 $0
Q3 2022 Nov 14, 2022	BUY	$3.46 - $6.0 $356 - $618	103 Added 63.19%	266 $1,000
Q2 2022 Aug 12, 2022	SELL	$3.23 - $7.4 $9,438 - $21,622	-2,922 Reduced 94.72%	163 $0
Q1 2022 May 16, 2022	SELL	$5.61 - $13.85 $64,638 - $159,579	-11,522 Reduced 78.88%	3,085 $19,000
Q4 2021 Feb 14, 2022	BUY	$10.52 - $16.96 $4,050 - $6,529	385 Added 2.71%	14,607 $184,000
Q3 2021 Nov 15, 2021	BUY	$9.82 - $15.23 $98,347 - $152,528	10,015 Added 238.06%	14,222 $180,000
Q2 2021 Aug 16, 2021	BUY	$13.27 - $26.0 $55,826 - $109,382	4,207 New	4,207 $59,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $55.5M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.